Differences in spending on provider-administered chemotherapy by site of care in Medicare.

CONCLUSIONS: Chemotherapy drug spending per Medicare beneficiary was lower in HOPDs than in physician offices, driven by less frequent use of chemotherapy in HOPDs. As the site of provider-administered chemotherapy shifts from physician offices to HOPDs, continuing assessment of cancer care spending by site of care is necessary. PMID: 30020752 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30020752?dopt=Abstract

Source: The American Journal of Managed Care - July 1, 2018 Category: Health Management Authors: Kalidindi Y, Jung J, Feldman R Tags: Am J Manag Care Source Type: research